| abstract |
Compounds comprising quinoxaline derivatives of formula I are described for use in the treatment of cancer. Overall, the compound inhibits the import of proteins and transcription factors such as Kpnα, AP‑1, P65, NFAT into the nucleus by inhibiting the nuclear import protein Kpnβ1. Cancer cells have elevated Kpnβ1 levels, and inhibition of its nuclear import activity induces apoptosis. Administration of an effective amount of either of these compounds results in apoptosis of cancer cells, while non-cancer cells are substantially unaffected by inhibition of nuclear import activity of Kpnβ1. |